P&G Health FY26: Sales up 16 percent, PAT up 30 percent, strong year delivered

Analyst Day Multiyear TargetsInvestor Communications View source PDF

PGHL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+1.6%1-day move

₹6220.00

prior close

₹6253.00

base price

In-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+0.1+0.4+0.3+0.2+1.6+1.3-0.3+0.5+0.3+1.6+9.5+9.9——

Up moveDown movePending

AI summary

P&G Health reported strong FY2025-26 results with sales up 16 percent and PAT up 30 percent year-on-year. After shifting its fiscal year to April-March, the firm highlighted a 5-year sales CAGR of 7 percent, PAT CAGR of 13 percent, and a 42 percent rise in ROE. Productivity savings of INR 35 crores were achieved. Key launches included Livogen Iron Gummies and Neurobion Nerve Pain Relief Cream. The Indian VMS category is growing at 9 percent CAGR amid widespread vitamin deficiencies. Long-term shareholder value creation was emphasised.

Likely market impact

Strong FY26 results reinforce P&G Health's consistent growth track record, likely to support positive investor sentiment and long-term shareholder value.